Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - omeprazole delayed-release capsules, usp, are indicated for short-term treatment of active duodenal ulcer in adults. most patients heal within four weeks. some patients may require an additional four weeks of therapy. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence. triple therapy omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with h. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate h. pylori in adults. dual therapy omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease to eradicate h. pylori in adults. among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. in patients who fail therapy, suscep

Մալայզիա - անգլերեն - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

averroes pharmaceuticals sdn. bhd. - rosuvastatin calcium -

Մալայզիա - անգլերեն - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

malaysian pharmaceutical industries sdn. bhd. - olanzapine -

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - omeprazole (unii: kg60484qx9) (omeprazole - unii:kg60484qx9) - omeprazole delayed-release capsules, usp, are indicated for short-term treatment of active duodenal ulcer in adults. most patients heal within four weeks. some patients may require an additional four weeks of therapy. eradication of h. pylori has been shown to reduce the risk of duodenal ulcer recurrence. triple therapy omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with h. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate h. pylori in adults. dual therapy omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with h. pylori infection and duodenal ulcer disease to eradicate h. pylori in adults. among patients who fail therapy, omeprazole delayed-release capsules with clarithromycin are more likely to be associated with the development of clarithromyc

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam oral solution, usp is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. information describing the use of levetiracetam in pediatric patients less than 4 years of age as adjunctive therapy in the treatment of partial onset seizures is approved for ucb, inc.'s levetiracetam tablets and oral solution. however, due to ucb, inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information. levetiracetam oral solution, usp is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. levetiracetam oral solution, usp is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy. levetiracetam is contraindicated in patients with a hypersensitivity to levetiracetam.

Իսրայել - անգլերեն - Ministry of Health

organon pharma israel ltd., israel - atorvastatin as calcium trihydrate; ezetimibe - film coated tablets - atorvastatin as calcium trihydrate 10 mg; ezetimibe 10 mg - atorvastatin and ezetimibe - - prevention of cardiovascular eventsatozet is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs), either previously treated with a statin or not.- hypercholesterolaemiaatozet is indicated as adjunctive therapy to diet for use in adults with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate• patients not appropriately controlled with a statin alone• patients already treated with a statin and ezetimibe- homozygous familial hypercholesterolaemia (hofh)atozet is indicated as adjunctive therapy to diet for use in adults with hofh. patients may also receive adjunctive treatments (e.g., low-density lipoprotein [ldl] apheresis).

Իսրայել - անգլերեն - Ministry of Health

organon pharma israel ltd., israel - atorvastatin as calcium trihydrate; ezetimibe - film coated tablets - atorvastatin as calcium trihydrate 20 mg; ezetimibe 10 mg - atorvastatin and ezetimibe - - prevention of cardiovascular eventsatozet is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs), either previously treated with a statin or not.- hypercholesterolaemiaatozet is indicated as adjunctive therapy to diet for use in adults with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate• patients not appropriately controlled with a statin alone• patients already treated with a statin and ezetimibe- homozygous familial hypercholesterolaemia (hofh)atozet is indicated as adjunctive therapy to diet for use in adults with hofh. patients may also receive adjunctive treatments (e.g., low-density lipoprotein [ldl] apheresis).

Իսրայել - անգլերեն - Ministry of Health

organon pharma israel ltd., israel - atorvastatin as calcium trihydrate; ezetimibe - film coated tablets - atorvastatin as calcium trihydrate 40 mg; ezetimibe 10 mg - atorvastatin and ezetimibe - - prevention of cardiovascular eventsatozet is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs), either previously treated with a statin or not.- hypercholesterolaemiaatozet is indicated as adjunctive therapy to diet for use in adults with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate• patients not appropriately controlled with a statin alone• patients already treated with a statin and ezetimibe- homozygous familial hypercholesterolaemia (hofh)atozet is indicated as adjunctive therapy to diet for use in adults with hofh. patients may also receive adjunctive treatments (e.g., low-density lipoprotein [ldl] apheresis).

Իսրայել - անգլերեն - Ministry of Health

organon pharma israel ltd., israel - atorvastatin as calcium trihydrate; ezetimibe - film coated tablets - atorvastatin as calcium trihydrate 80 mg; ezetimibe 10 mg - atorvastatin and ezetimibe - - prevention of cardiovascular eventsatozet is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs), either previously treated with a statin or not.- hypercholesterolaemiaatozet is indicated as adjunctive therapy to diet for use in adults with primary (heterozygous familial and non-familial) hypercholesterolaemia or mixed hyperlipidaemia where use of a combination product is appropriate• patients not appropriately controlled with a statin alone• patients already treated with a statin and ezetimibe- homozygous familial hypercholesterolaemia (hofh)atozet is indicated as adjunctive therapy to diet for use in adults with hofh. patients may also receive adjunctive treatments (e.g., low-density lipoprotein [ldl] apheresis).

Սաուդյան Արաբիա - անգլերեն - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

om pharma - ethamsylate - solution for injection - 125 mg/ml